The long-term goal of this proposal is to elucidate the role and mechanisms of class I histone deacetylases (HDACs) in renal fibrosis. Chronic kidney disease (CKD) leading to end-stage kidney failure is associated with interstitial renal fibrosis regardless of the underlying cause. So far, there are no specific clinical treatments to target fibrosis. Renal fibrosis is characterized by aberrant activation and growth of renal interstitial fibroblasts. The activated fibroblast has been termed a myofibroblast and is defined by phenotypic changes such as the expression of -smooth muscle actin (-SMA). As myofibroblasts are able to proliferate rapidly and produce excessive matrix proteins (i.e. fibronectin) that contribute to the pathology of renal fibrosis, an approach that inhibits renal fibroblast activation and proliferation may attenuate or halt the progression of CKD. Our preliminary data demonstrate that: 1) treatment with trichostatin A (TSA), a specific inhibitor of class I/II histone deacetylases (HDACs), inhibits cell proliferation and expression of -SMA and fibronectin in cultured rat renal interstitial fibroblasts (NRK-49F) and in the fibrotic kidney induced by unilateralureteral obstruction (UUO) injury;2) Proliferation and activation of renal interstitial fibroblasts are accompanied by phosphorylation of signal transducer and activator of transcription 3 (STAT3);3) Blockade of the STAT3 pathway also inhibits activation and proliferation of NRK-49F;and 4) TSA abolishes STAT3 phosphorylation in NRK-49F and in the kidney following obstructive injury. From these data, we hypothesize that HDACs-mediated activation of STAT3 regulates activation and proliferation of renal interstitial fibroblasts and progression of renal fibrosis.
Specific Aim1 will define the role of the class I HDAC isoforms in regulating cell proliferation and activation and global protein expression and lysine acetylation in renal interstitial fibroblasts.
Specific Aim 2 will elucidate the mechanism of class I HDAC-mediated activation of STAT3 in renal interstitial fibroblasts.
Specific Aim 3 will evaluate the therapeutic effect of class I HDAC and STAT3 inhibitors on the progression of renal fibrosis following obstructive injury. Successful completion of these studies will increase our knowledge of the mechanisms of renal fibrosis and facilitate the development of HDAC inhibitors as novel treatments for CKD.

Public Health Relevance

Renal tubulointerstitial fibrosis is characterized by aberrant activation and growth of the renal fibroblasts. As histone deacetylase (HDAC) inhibitors are being investigated as potential anticancer drugs, elucidation of the functional role and mechanism of HDACs in the activation and proliferation of renal interstitial fibroblasts could lead to use of HDAC inhibitors as therapeutic agents for chronic kidney disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK085065-03
Application #
8308655
Study Section
Pathobiology of Kidney Disease Study Section (PBKD)
Program Officer
Kimmel, Paul
Project Start
2010-09-30
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
3
Fiscal Year
2012
Total Cost
$317,382
Indirect Cost
$111,957
Name
Rhode Island Hospital
Department
Type
DUNS #
075710996
City
Providence
State
RI
Country
United States
Zip Code
02903
Ponnusamy, Murugavel; Zhou, Xiaoxu; Yan, Yanli et al. (2014) Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy. J Pharmacol Exp Ther 350:243-56
Tang, Jinhua; Yan, Yanli; Zhao, Ting C et al. (2014) Class I HDAC activity is required for renal protection and regeneration after acute kidney injury. Am J Physiol Renal Physiol 307:F303-16
Tang, Jinhua; Yan, Yanli; Zhao, Ting C et al. (2013) Class I histone deacetylase activity is required for proliferation of renal epithelial cells. Am J Physiol Renal Physiol 305:F244-54
Tang, Jinhua; Yan, Haidong; Zhuang, Shougang (2013) Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond) 124:651-62
Ponnusamy, Murugavel; Ma, Li; Zhuang, Shougang (2013) Necrotic renal epithelial cell inhibits renal interstitial fibroblast activation: role of protein tyrosine phosphatase 1B. Am J Physiol Renal Physiol 304:F698-709
Tang, Jinhua; Liu, Na; Tolbert, Evelyn et al. (2013) Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury. Am J Pathol 183:160-72
Tang, Jinhua; Liu, Na; Zhuang, Shougang (2013) Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney Int 83:804-10
He, Song; Liu, Na; Bayliss, George et al. (2013) EGFR activity is required for renal tubular cell dedifferentiation and proliferation in a murine model of folic acid-induced acute kidney injury. Am J Physiol Renal Physiol 304:F356-66
Liu, Na; He, Song; Ma, Li et al. (2013) Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS One 8:e54001
Zhuang, Shougang (2013) Regulation of STAT signaling by acetylation. Cell Signal 25:1924-31

Showing the most recent 10 out of 18 publications